HC Wainwright Reiterates “Buy” Rating for Kamada (NASDAQ:KMDA)

HC Wainwright reissued their buy rating on shares of Kamada (NASDAQ:KMDA) in a research note published on Thursday,Benzinga reports. The firm currently has a $11.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Kamada’s Q4 2024 earnings at $0.05 EPS, FY2025 earnings at $0.26 EPS, FY2026 earnings at $0.38 EPS, FY2027 earnings at $0.45 EPS and FY2028 earnings at $0.53 EPS.

Separately, StockNews.com downgraded Kamada from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 27th.

Kamada Price Performance

Shares of Kamada stock traded down $0.10 during trading on Thursday, hitting $5.76. 17,695 shares of the company were exchanged, compared to its average volume of 29,805. The firm has a market capitalization of $331.08 million, a P/E ratio of 20.89 and a beta of 1.05. The firm’s fifty day moving average price is $5.47 and its 200 day moving average price is $5.46. Kamada has a 1-year low of $4.60 and a 1-year high of $6.53.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The firm had revenue of $42.47 million during the quarter, compared to analysts’ expectations of $39.70 million. Kamada had a net margin of 9.92% and a return on equity of 6.36%. As a group, equities research analysts anticipate that Kamada will post 0.26 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Plato Investment Management Ltd acquired a new stake in shares of Kamada during the third quarter worth $117,000. Y.D. More Investments Ltd increased its holdings in Kamada by 1,956.0% during the 2nd quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company’s stock worth $3,643,000 after purchasing an additional 690,842 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Kamada by 8.2% in the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock valued at $7,433,000 after purchasing an additional 100,800 shares during the period. Institutional investors and hedge funds own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.